Newsgroup: it.economia.borsa
Titolo: short interest CELL TH (SA)

ultimo dato
lo short interest continua a calare
da 8,275.000 a 7,500.000



 da 8,275.000 a 7,500.000
come previsto chiudono poco alla volta senza farsi notare ;o)))) mi tengo le
mie cell a 1.65 a dicembre si vedra' .

 ha scritto nel messaggio 
news:44041b05$0$28078$4faf...@reader1.news.tin.it...


 Non è poco ???
li chiudono poco alla volta perché di più non possono: se chiudessero tutti 
assieme si ripeterebbe il +50% in poche ore di novembre :-OOO
loro già conoscono più o meno i tempi delle novità e vedrai che non si 
faranno tenere impreparati, noi dobbiano solo seguire i volumi e news come 
questa che ci hai dato te;
mascherò, tienici informati sempre sulla chiusura degli scort su cell anche 
nei prossimi mesi :-)) 

 nei prossimi mesi :-))
mi associo grazie e bravo mascheroni non tradisce mai!!!!!!!!!


*** concordo con entrambi :-)) 


il 21 febbraio
He said a few multinational pharmaceutical companies have been particularly
interested in the drug's gender-specific effect and the company hopes to
sign up a commercial partner.
In order to do that, Cell Therapeutics would like to regain rights to the
drug in Japan and other Asian countries that are now held by Chugai
Pharmaceutical Co. Ltd.
Such an announcement is likely "within the next few weeks," Bianco said.

aggoingo che in america si vogliono tagliare i costi della spesa
farmaceutica  e della sanità in generale
sempre dalla conference del 21 febbraio:
(BIANCO)
He said economic studies have shown that Xyotax would save $47,000 per
patient per year of survival because it would limit the need for drugs that
treat side effects of chemotherapy as well as additional hospitalizations

 aggiungo che in america si vogliono tagliare i costi della spesa


      Cell Therapeutics, Inc. Hires Former BIO VP of Communications
          Dan Eramian to Join CTI as EVP of Corporate CommunicationsSEATTLE,
Feb. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq:
CTIC) today announced that Dan Eramian, former Vice President of
Communications at Biotechnology Industry Organization (BIO), will join the
Company in early March as Executive Vice President of Corporate
Communications. Eramian will serve as a member of the Company's senior
management team and will be responsible for developing and implementing the
internal and external communications strategy. Eramian brings nearly 13
years of experience in the biotechnology industry to the position.
      "We are very pleased to have Dan join the senior management team. His
wealth of industry knowledge and experience has earned him the trust and
respect of his colleagues," said James A. Bianco, M.D., President and CEO of
CTI. "We are confident that his experience and leadership will be an asset
to CTI."
      Most recently Eramian was Vice President of Communications at BIO, a
Washington, DC-based industry organization representing more than 1,200
biotechnology companies, academic institutions, state biotechnology centers
and related organizations. Prior to BIO, Eramian was Assistant Administrator
of Communications at the Small Business Administration and Director of
Public Affairs at the Department of Justice and Chief Spokesman for the
Attorney General.
      "In my 13 years at BIO, I have worked with scores of fine CEOs and
member companies," stated Eramian. "I am especially excited about joining
the CTI team and contributing to their bright future."
      "CTI has landed a significant asset. Dan Eramian is a highly
experienced professional and has performed exceptionally well at the
international, national, and local levels without ever losing his rare
common touch," noted Carl B. Feldbaum, president emeritus and former
president of BIO.